Nexavar Survival Study In Asia-Pacific Patients With Liver Cancer Halted Early
This article was originally published in PharmAsia News
Executive Summary
Bayer and Onyx Pharmaceuticals announced Aug. 27 that a trial evaluating Nexavar (sorafenib) in Asia-Pacific patients with hepatocellular carcinoma will be stopped early to allow all patients to receive the drug based on positive study results and the recommendation of an independent data monitoring committee
You may also be interested in...
Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market
BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound
Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market
BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound
Banner Week For Bayer In Japan
TOKYO - For the third time in a week Bayer released positive news related to Japan, saying Jan. 28 it had received marketing approval from the Ministry of Health, Labor and Welfare for Nexavar (sorafenib) for the treatment of advanced renal cell carcinoma. Four days earlier, the German company had said Nexavar received priority review from MHLW for the treatment of hepatocelluar carcinoma, a larger potential market